Also it is noteworthy that the data shown on slides 17 and 18 were updated September 20, 2017. There's about a month of data not reflected in the graphs yet. Those 3 patients in Cohort 2 who have already exceeded the enzalutamide-alone standard of care timeline by several weeks for progression free survival and PSA response would be even further along if the graph was updated (assuming patient trend continued).....very close to crossing the "target" threshhold set by Zenith. And the next highest ZEN-3694 dose Cohort 3, who started after Cohort 2, would be close to exceeding the enzlutamide-alone standard of care by now if the data were current. They still haven't arrived at the max tolerated dose of ZEN-3694 for this combo trial, so the fact that Cohort 2 is performing so well is extremely encouraging!

BearDownAZ